Table 4.
Age-, sex-, race/ethnicity-, and insurance-adjusted risk ratio estimates for quality-of-care indicators by ESRD Network, among US patients in whom treatment for ESRD attributed to lupus nephritis was initiated between July 1, 2005 and September 30, 2011*
| Network | Odds ratio (95% CI) for having received pre-ESRD nephrology care | Odds ratio (95% CI) for being informed of transplant options | Hazard ratio (95% CI) for kidney transplant waitlisting | Odds ratio (95% CI) for having fistula/graft in place at first dialysis | |
|---|---|---|---|---|---|
|
| |||||
| In first year after start of ESRD treatment | After first year of ESRD treatment | ||||
| 1 (CT, ME, MA, NH, RI, VT) | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) |
| 2 (NY) | 0.63 (0.40–1.02) | 1.33 (0.78–2.28) | 1.56 (1.05–2.32) | 1.27 (0.79–2.06) | 1.07 (0.70–1.63) |
| 3 (NJ) | 0.47 (0.29–0.78) | 1.73 (0.93–3.21) | 1.10 (0.71–1.70) | 0.76 (0.43–1.33) | 1.12 (0.70–1.78) |
| 4 (DE, PA) | 0.64 (0.37–1.08) | 1.09 (0.60–1.98) | 1.78 (1.16–2.73) | 0.56 (0.29–1.09) | 0.79 (0.49–1.28) |
| 5 (DC, MD, VA, WV) | 0.59 (0.36–0.96) | 1.20 (0.69–2.09) | 0.85 (0.55–1.32) | 0.83 (0.50–1.38) | 0.72 (0.46–1.14) |
| 6 (GA, NC, SC) | 0.68 (0.43–1.08) | 0.93 (0.57–1.53) | 0.60 (0.40–0.90) | 0.95 (0.60–1.51) | 0.74 (0.49–1.12) |
| 7 (FL) | 0.55 (0.34–0.88) | 1.15 (0.68–1.95) | 0.38 (0.24–0.61) | 0.89 (0.55–1.44) | 0.58 (0.37–0.91) |
| 8 (AL, MS, TN) | 0.58 (0.36–0.93) | 1.48 (0.85–2.58) | 0.99 (0.65–1.50) | 0.85 (0.52–1.41) | 1.09 (0.71–1.68) |
| 9 (IN, KY, OH) | 0.60 (0.36–0.98) | 1.17 (0.67–2.02) | 0.61 (0.39–0.97) | 0.82 (0.49–1.37) | 0.57 (0.36–0.91) |
| 10 (IL) | 0.45 (0.27–0.73) | 1.29 (0.73–2.29) | 1.02 (0.66–1.57) | 0.82 (0.49–1.38) | 0.47 (0.29–0.77) |
| 11 (MI, MN, ND, SD, WI) | 0.65 (0.40–1.06) | 0.90 (0.53–1.53) | 0.85 (0.56–1.31) | 0.91 (0.55–1.49) | 0.57 (0.36–0.90) |
| 12 (IA, KS, MO, NE) | 0.61 (0.36–1.06) | 0.88 (0.48–1.62) | 0.67 (0.39–1.13) | 0.69 (0.38–1.26) | 0.53 (0.31–0.91) |
| 13 (AR, LA, OK) | 0.48 (0.29–0.79) | 0.88 (0.51–1.53) | 0.61 (0.38–0.99) | 0.68 (0.39–1.16) | 0.65 (0.40–1.05) |
| 14 (TX) | 0.51 (0.32–0.80) | 1.48 (0.89–2.46) | 0.74 (0.50–1.10) | 0.98 (0.62–1.55) | 0.89 (0.59–1.35) |
| 15 (AZ,CO, NM, NV, UT, WY) | 0.54 (0.33–0.88) | 1.01 (0.59–1.75) | 0.76 (0.49–1.18) | 0.69 (0.41–1.15) | 0.68 (0.43–1.08) |
| 16 (AK, ID, MT, OR, WA) | 0.99 (0.54–1.84) | 0.86 (0.46–1.63) | 0.60 (0.34–1.07) | 0.66 (0.35–1.24) | 1.14 (0.66–1.96) |
| 17 (HI, Northern CA) | 0.71 (0.42–1.18) | 0.88 (0.51–1.53) | 1.96 (1.31–2.94) | 0.86 (0.49–1.48) | 0.96 (0.61–1.53) |
| 18 (Southern CA) | 0.46 (0.28–0.74) | 1.16 (0.69–1.95) | 0.70 (0.46–1.07) | 0.84 (0.51–1.36) | 0.51 (0.33–0.80) |
*
ESRD = end-stage renal disease; 95% CI = 95% confidence interval; ref. = referent.